Ten Years at Vertex: An Interview with David Altshuler.

David Altshuler, a physician-scientist specializing in human genome analysis and diabetes, joined Vertex Pharmaceuticals in 2015 as Executive Vice President and Chief Scientific Officer. Altshuler, along with then-CEO Jeff Leiden, reworked the company's R&D strategy to focus on serious genetic diseases, leading to successful therapeutic programs in cystic fibrosis, sickle cell disease, and transfusion-dependent thalassemia. Altshuler's interview with Kevin Davies at The State of Biotech summit highlighted Vertex's innovative approach to drug discovery and development, including the groundbreaking CRISPR-based cell therapy for sickle cell and thalassemia. The company's commitment to developing transformative medicines and improving patient outcomes is evident in their ongoing research and dedication to addressing unmet medical needs. [Extracted from the article]